Otolith Labs Email Format

Biotechnology ResearchDistrict of Columbia, United States11-50 Employees

Otolith Labs is a biotechnology research company focused on treating chronic vertigo through a non-invasive wearable approach. It has developed Vestibular Resonance Therapy (nVRT), designed to deliver energy to the vestibular system in order to alleviate vertigo symptoms. The technology has received FDA Breakthrough Device Designation, reflecting its potential to address a broad vestibular disorder indication. The company operates from Washington, D.C., and aims to move its regulatory clearances forward in the U.S. and beyond.

With a team described as small to mid-sized, Otolith Labs targets patients with vertigo and clinicians who treat vestibular disorders, offering a non-invasive treatment option. In May 2024, the company announced the appointment of Kevin Franck as Chief Clinical Officer to strengthen its clinical leadership.

Sign up for free to view info

Company overview Employee directory